33 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
”), diversifying our pipeline of non-opioid pain treatment therapies, while adding therapeutic options for related conditions. The sublingual formulation
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
”), diversifying our pipeline of non-opioid pain treatment therapies, while adding therapeutic options for related conditions. The sublingual formulation
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
sublingual spray formulation (collectively, the “Spray Formulations”), diversifying our pipeline of non-opioid pain treatment therapies, while adding
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
dominated by opioid analgesics. Opioid analgesics decrease the perception of pain by stimulating a range of opioid receptors that modulate pain signals … . The most widely used opioid analgesics, including morphine, fentanyl and hydromorphone, act primarily through the activation of mu opioid receptors
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
dominated by opioid analgesics. Opioid analgesics decrease the perception of pain by stimulating a range of opioid receptors that modulate pain signals … . The most widely used opioid analgesics, including morphine, fentanyl and hydromorphone, act primarily through the activation of mu opioid receptors
10-K
35se1hgg i83
16 Apr 24
Annual report
4:48pm
8-K
EX-99.1
2ecflxx 9zvls
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
8-K
EX-99.1
k9n9dy
21 Mar 24
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
9:00am
8-K
EX-99.1
pa37viev17
18 Mar 24
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
4:05pm
8-K
EX-99.1
9dbxo1nu
13 Mar 24
Regulation FD Disclosure
8:00am
8-K
EX-99.1
ezsj3t0
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-99.2
d4vb5x
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
9pozmv5pteeqj1
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
q3xj4v jlhb
20 Feb 24
Prospectus supplement with pricing info
5:28pm
FWP
65qn7bnwet7
12 Feb 24
Free writing prospectus
8:09am
FWP
rvsq59 k5
6 Feb 24
Free writing prospectus
8:43pm
FWP
ksl6bjsweqc44
31 Jan 24
Free writing prospectus
4:16pm